Assessment of strategies to increase chondrocyte viability in cryopreserved human osteochondral allografts: evaluation of the glycosylated hydroquinone, arbutin  by Rosa, S.C. et al.
Osteoarthritis and Cartilage (2009) 17, 1657e1661
ª 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.joca.2009.08.016
International
Cartilage
Repair
SocietyBrief report
Assessment of strategies to increase chondrocyte viability in
cryopreserved human osteochondral allografts: evaluation of the
glycosylated hydroquinone, arbutin
S. C. Rosay, J. Gonc¸alvesy, F. Judasz, C. Lopesy and A. F. Mendesy*
yCenter for Neurosciences and Cell Biology and Faculty of Pharmacy, University of Coimbra, 3004-517
Coimbra, Portugal
zBone and Tissue Bank, Orthopaedics Department, University Hospital of Coimbra, Avenida Bissaya
Barreto, Bloco de Celas, 3000-075 Coimbra, Portugal
Summary
Objective: Allogeneic cartilage is used to repair damaged areas of articular cartilage, requiring the presence of living chondrocytes. So far, no
preservation method can effectively meet that purpose. Identiﬁcation of more effective cryoprotective agents (CPAs) can contribute to this
goal. The aim of this study was to determine whether the glycosylated hydroquinone, arbutin, alone or in combination with low concentrations
of other CPAs, has cryoprotective properties towards human articular cartilage.
Material and methods: Human tibial plateaus were procured from multi-organ donors, with the approval of the Ethics Committee of the Uni-
versity Hospital of Coimbra. The tibial plateaus were treated with or without arbutin (50 or 100 mM), alone or in combination with various con-
centrations of dimethyl sulfoxide (DMSO) and glycerol, for 0.5e1.5 h/37C, then frozen at 20C and 24 h later transferred to a biofreezer at
80C. Two to 3 months later, thawing was achieved by immersion in cell culture medium at 37C/1 h. Chondrocyte viability was assessed
before and after freezeethawing using a colorimetric assay based on the cell’s metabolic activity and ﬂuorescent dyes to evaluate cell mem-
brane integrity.
Results: Before freezing, chondrocyte metabolic activity was identical in all the conditions tested. After freezeethawing, the highest activity,
corresponding to 34.2 2.1% of that in the Fresh Control, was achieved in tibial plateaus incubated in 50 mM arbutin for 1 h whereas in those
left untreated it was 11.1 4.7. Addition of DMSO and glycerol to arbutin did not increase chondrocyte viability any further. Fluorescence mi-
croscopy conﬁrmed these results and showed that living chondrocytes were mainly restricted to the superﬁcial cartilage layers.
Conclusion: Arbutin seems to be an effective cryoprotective agent for osteochondral allografts with potential beneﬁts over DMSO and glycerol.
ª 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Damage to articular cartilage because of trauma, degener-
ative and tumour diseases, or infection represents a major
clinical problem. Of the existing treatment alternatives, the
transplantation of osteochondral grafts is increasingly em-
ployed as means of biological resurfacing for articular carti-
lage defects. Osteochondral grafts, consisting of an
articular cartilage layer and the underlying subchondral
bone, can either be collected from the patient (autografts)1
or from multi-organ donors (allografts)2,3 which, unlike auto-
grafts, allow the treatment of large cartilage defects4,5.
Cryopreserved allografts enable size-matching of the allo-
graft and the recipient, screening of infectious diseases of
the donor and quarantine of the allografts, which are manda-
tory for safe transplantation, and transportation of tissues to
distant locations.3 However, the clinical outcome of*Address correspondence and reprint requests to: Alexandrina
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1657cryopreserved vs fresh osteochondral allografts is poor and
formationof ﬁbrocartilage, chondromalacia and loss of the car-
tilage surfaces occur frequently sometime after implantation,
leading toa variable graft failure rate of 10e50%.3 Theefﬁcacy
of the transplanted osteochondral grafts seems to be propor-
tional to their content of living chondrocytes6e8. Since these
cells are essential to maintain cartilage matrix integrity9, any
injury that kills even a small number, can have severe conse-
quences on cartilage integrity and durability.8 Cryoprotective
agents (CPAs), such as glycerol or dimethyl sulfoxide
(DMSO), effectively protect isolated chondrocytes from the
damaging effects of freezing.10 However, freezing of intact ar-
ticular cartilage, even in the presence of the same CPAs, seri-
ously compromises chondrocyte viability7,8,11e14.
In most studies, a maximum of 20e30% of the cartilage
chondrocytes were reported to survive freezing when CPAs,
such as DMSO or glycerol, were employed11,12,14, whereas,
in their absence, none or a very small number of viable chon-
drocytes was retrieved14,15. The CPAs currently available are
cytotoxic, depending on the duration and temperature of expo-
sure and on the concentrations used. To avoid toxicity, most
cryopreservation protocols use low temperatures of exposure
1658 S. C. Rosa et al.: Cartilage cryoprotection by arbutinto the CPAs11,12. However, Carsi and co-workers15 found that
the diffusion of either DMSO or glycerol through human artic-
ular cartilage decreased at lower temperatures and with in-
creasing concentrations. Thus, identiﬁcation of less toxic
CPAs should allow longer exposure times at higher tempera-
tures, probably eliciting amore effective cryoprotection. Possi-
ble strategies based on this principle are the combination of
low concentrations of various CPAs and the identiﬁcation of
new more effective and less toxic CPAs. In this regard, com-
pounds extracted from organisms naturally resistant to
drought and cold are being evaluated for cryoprotective prop-
erties. One such compound is arbutin (4-hydroxyphenyl-b-D-
glucopyranoside, Fig. 1), a glycosylated hydroquinone that
has been shown to have a membrane stabilizing effect and
to protect isolated cell membranes and liposomes from the
damaging effects of both freezeethawing and drying16,17.
The purpose of this study was to determine whether arbutin
hascryoprotectiveproperties towardshumanarticular cartilage.
For this and based on the strategies identiﬁed above, we eval-
uated the ability of arbutin, alone and in combination with low
concentrations of DMSO and glycerol, to increase the recovery
of viable chondrocytes from frozen/thawed whole human tibial
plateaus, which represent a good model of the whole bone.Materials and methodsREAGENTSThe acetomethoxy ester of Calcein, Calcein AM (Cal), was purchased
from Molecular Probes (Eugene, OR). All other reagents were from Sigma
Chemical Co. (St. Louis, MO).OSTEOCHONDRAL SAMPLESAs a model of the whole bone, the right and left lateral and medial tibial
plateaus, composed of the intact articular cartilage and an underlying bony
layer of 0.5e1.5 cm thick, were harvested from 18 multi-organ donors (10
males and 8 females) and processed within 24 h post-mortem, according
to the standards of the Tissue Bank of the University Hospital of Coimbra
(HUC), Portugal, and the Portuguese Transplantation Organization. Donor
age ranged from 17 to 53 years old. All the tibial plateaus used appeared
macroscopically normal without signs of cartilage damage. All the proce-
dures had the approval of the Ethics Committee of HUC.CRYOPROTECTION TREATMENTS AND FREEZEeTHAWING
CONDITIONSImmediately upon harvesting, the tibial plateaus were incubated at 37C
for 0.5e1.5 h in Ham F-12 nutrient mixture in the presence or absence of
50 or 100 mM arbutin, alone or in combination with DMSO and glycerol in
the concentrations indicated in the ﬁgures and legends. Then, the tibial pla-
teaus were removed from the cryoprotective solutions, placed in sterile plas-
tic bags, frozen at 20C/24 h, transferred to a biofreezer at 80C and kept
in those conditions for 2e3 months. Thawing was achieved by immersion in
Ham F-12 nutrient mixture at 37C/1 h.EVALUATION OF CHONDROCYTE VIABILITY IN SITUChondrocyte viability in situ was assessed before freezing and after thaw-
ing. For this, two cartilage cylinders were cut with a 5 mm diameter trephineFig. 1. Chemical structure of arbut in (4-hydroxyphenyl-
b-D-glucopyranoside).from each tibial plateau immediately before freezing and twelve identical cyl-
inders were obtained immediately after thawing. Two methods were used to
evaluate chondrocyte viability: (1) an adaptation18 of the 3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium (MTT) reduction assay19 which is a quantita-
tive colorimetric method based on the reduction of the MTT salt by the
mitochondrial enzymes of viable cells; and (2) a cell membrane integrity as-
say using a ﬂuorescent dye combination consisting of Cal and Propidium Io-
dide (PI). Cal is a cell membrane-permeable ester that upon hydrolysis by
intracellular esterases, emits green ﬂuorescence and becomes cell mem-
brane-impermeable, being retained within cells bearing an intact plasma
membrane. PI is cell membrane-impermeable and stains the nuclei of cells
with damaged membranes with strong red ﬂuorescence.
The two cylinders collected from each tibial plateau before freezing and
ten of those collected after thawing were weighted and incubated in Ham
F-12 Nutrient Mixture containing 1 mg/ml MTT, for 1 h at 37C. The dark
blue crystals of formazan produced by reduction of the MTT salt were dis-
solved in acidiﬁed isopropanol and quantiﬁed in an automatic plate reader
(Tecan/SLT Instruments, Austria) set at a test wavelength of 570 nm and
a reference wavelength of 620 nm.
The remaining two cylinders collected after thawing were incubated at
37C for 30 min in phosphate buffered saline containing 5 mM Cal and
5 mg/ml PI. Cryostat sections 30 mm thick were obtained from each cylinder
and viewed under a ﬂuorescence microscope.DATA ANALYSISWhere applicable, statistical analysis was performed using one-way
analysis of variance with Dunnett’s post test. Results were considered signif-
icant for P< 0.05.Results
The MTT reduction assay preformed in fresh cartilage im-
mediately before freezing [Fig. 2(A)], showed that arbutin did
not affect the ability of chondrocytes to reduce the MTT salt,
as compared to chondrocytes in cartilage incubated in cul-
ture medium alone (Control). These results showed that ar-
butin was not toxic, nor increased the metabolic activity of
chondrocytes in situ, under the conditions tested.
After freezeethawing, the metabolic activity of chondro-
cytes in tibial plateaus pre-incubated with 50 or 100 mM
arbutin for 0.5 or 1 h, was compared to that in the fresh and
Post-thawed Controls. As shown in Fig. 2(B), chondrocyte
metabolic activity relative to the Fresh Control, which corre-
sponds to the condition of maximal viability, was signiﬁcantly
reduced in all conditions tested. Nevertheless, it was signiﬁ-
cantly higher in tibial plateaus exposed to arbutin, in any of
the conditions tested, than in the Postethawed Control,
which represents the lowest viability, corresponding to
11.1 4.7% of the metabolic activity of the Fresh Control.
The highest activity, corresponding to 34.2 2.1% of the
Fresh Control, was achieved in tibial plateaus incubated in
50 mM arbutin for 1 h, but a shorter incubation period
(30 min) elicited almost the same activity (32.0 5.4%). In-
creasing arbutin concentration to 100 mM resulted in
a slightly lower activity of 28.5 2.8% relative to the Fresh
Control, although the difference was not statistically
signiﬁcant.
Attempting to further enhance in situ chondrocyte cryo-
protection without signiﬁcantly increasing direct toxicity,
we tested various combinations of low concentrations of
DMSO and glycerol with arbutin and extended the incuba-
tion period to 1.5 h, hypothesising that diffusion of the
CPAs could be improved. The results showed that before
freezing, the differences between conditions were not sta-
tistically signiﬁcant, although mean values were slightly var-
iable [Fig. 3(A)]. After freezeethawing, MTT reduction
relative to that obtained in the Fresh Control, was signiﬁ-
cantly higher with any of the combinations tested than in
the Post-thawed Control [Fig. 3(B)], but slightly lower than
the highest activity obtained with arbutin alone [Fig. 2(B)].
Fig. 2. Chondrocyte viability, measured by the MTT reduction as-
say, in tibial plateaus treated with arbutin. (A) chondrocyte viability,
expressed in percentage of the Control which was taken as 100%,
in fresh tibial plateaus incubated for the periods indicated in the ab-
sence (Control) or presence of the indicated concentrations of arbu-
tin. (B) chondrocyte viability, expressed in percentage relative to
fresh cartilage incubated in culture medium alone (Fresh Control),
in freezeethawed tibial plateaus previously incubated for the pe-
riods indicated in the absence (Post-thawed Control) or presence
of the indicated concentrations of arbutin. Each bar represents
the mean S.E.M. of six independent experiments. #P< 0.05 and
# #P< 0.01 compared to the Postethawed Control; ***P< 0.001
compared to the Fresh Control.
Fig. 3. Chondrocyte viability, measured by the MTT reduction as-
say, in tibial plateaus treated with combinations of arbutin, DMSO
and glycerol. (A) chondrocyte viability, expressed in percentage
of the Control which was taken as 100%, in fresh tibial plateaus in-
cubated for 1.5 h in the absence (Control) or presence of the indi-
cated concentrations of arbutin combined with 5% (2.5%
DMSOþ 2.5% glycerol) or 10% (5% DMSOþ 5% glycerol) CPAs.
(B) chondrocyte viability, expressed in percentage relative to fresh
cartilage incubated in culture medium alone (Fresh Control), in
freezeethawed tibial plateaus previously incubated for the periods
indicated in the absence (Post-thawed Control) or presence of the
indicated concentrations of arbutin combined with 5% (2.5%
DMSOþ 2.5% glycerol) or 10% (5% DMSOþ 5% glycerol) CPAs.
Each bar represents the mean S.E.M. of, at least, six independent
experiments. #P< 0.05, ##P< 0.01 and ###P< 0.001 compared to
the Postethawed Control; ***P< 0.001 compared to the Fresh
Control.
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ber and distribution of viable chondrocytes was similar in the
three conditions using arbutin [Fig. 4(B, C, D)], whereas in
the Postethawed Control very few or no viable cells were
observed [Fig. 4(A)]. When compared to cartilage sections
pre-treated with 10% DMSO [Fig. 4(E)] or 10% glycerol
[Fig. 4(F)] for 30 min at 37C, used as positive standards,
the apparent number of viable chondrocytes was higher in
those treated with arbutin, either alone [Fig. 4(B)] or in com-
bination with those CPAs [Figs. 4(C, D)]. These results
conﬁrmed those of the MTT reduction assay and showed
that, even in the condition eliciting the highest activity
(50 mM arbutin/1 h), viable chondrocytes were mainly
restricted to the superﬁcial cartilage layers [Fig. 4(B)]. Cell
density in each cartilage section was estimated by observing
the cells stained with PI [Fig. 4(aef)] and by viewing each
section under light transmission. No apparent differences
were observed between the different conditions tested intibial plateaus obtained from the same donor, although
some variability, unrelated to age or gender, was observed
among different donors.Discussion
The results presented show that arbutin increased themet-
abolic activity in frozenethawed tibial plateaus to amaximum
of 34%of the FreshControl. Some studies indicate, however,
that metabolic activity assays overestimate cell viability due
to activation by cold exposure, whereas membrane integrity
stains seem to reﬂect cell viability more accurately11,20.
This is also probably the case in our study since ﬂuorescence
microscopy showed only very few viable chondrocytes in the
Postethawed Control, whereas metabolic activity in the
same samples represented 11% of the Fresh Control.
Our previous study, using the same osteochondral model
and experimental conditions (temperature of incubation with
Fig. 4. Chondrocyte viability and cell density evaluated as a function
of cell membrane integrity by ﬂuorescence microscopy of cartilage
sections stained with Cal (A, B, C, D, E, F) and PI (a, b, c, d, e, f).
Representative ﬂuorescence microscopy photographs of full depth
cartilage sections obtained from frozenethawed tibial plateaus left
untreated (A, a) or pre-treated at 37C with 50 mM arbutin/1 h (B,
b), 50 mM arbutin plus 5% CPAs (2.5% DMSOþ 2.5% glycerol)/
1.5 h (C, c), 100 mM arbutin plus 10% CPAs (5% DMSOþ 5% glyc-
erol)/1.5 h (D, d), 10% DMSO/30 min (E, e) or 10% glycerol/30 min
(F, f). Chondrocytes with intact cell membranes are stained in green
and those with damaged cell membranes are stained in red (100).
The images shown are representative of at least four independent
experiments for each condition.
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similar to those described in the current study, showed that
treatment with 10%DMSOor 10%glycerol increased themet-
abolic activity in the frozenethawed tibial plateaus to approxi-
mately 15% of the Fresh Control.14 Thus, comparatively, the
cryoprotective effect of arbutin was approximately twice that
elicited by thoseCPA. It can beargued that arbutinmay simply
have increased themetabolic activity of the cells that survived
freezeethawing, but since before freezing, arbutin, either
alone or in combination, did not affect the metabolic activity
of chondrocytes (Fig. 2), that hypothesis is unlikely.
On the other hand, if the metabolic activities were cor-
rected by subtracting the result of the Postethawed Control
from that of each experimental condition, viability in tibial
plateus treated with arbutin 50 mM/1 h would be approxi-
mately 23%, whereas in those treated with 10% DMSO or
10% glycerol it would not exceed 4%.
In either case, the ability of arbutin to preserve the meta-
bolic activity and likely the viability of chondrocytes is signif-
icantly higher than that of DMSO or glycerol tested under
similar conditions. Moreover, if compared to the results re-
ported for DMSO and glycerol in studies using small osteo-
chondral cylinders, the metabolic activity obtained with
arbutin is within the same range6,12,21. Since the surface
area through which the CPAs can diffuse through the artic-
ular cartilage is considerably smaller and the volume much
larger in the whole tibial plateaus than in the small osteo-
chondral cylinders generally used, the results obtained
with arbutin in our study seem especially relevant.
Although not quantitatively expressed, evidence from
membrane integrity stains also indicates that treatment
with arbutin, either alone or in combination with traditional
CPAs, increases the recovery of viable chondrocytes.
Nonetheless, viable chondrocytes were still restricted to
the superﬁcial cartilage layers, even when cryoprotective
treatment was extended to 1.5 h. This suggests that none
of the compounds used reached the entire cartilage depth,
as also found in other studies with DMSO and glycerol7,14.
Additionally, the conditions used in our study for the cry-
oprotection treatments are easily applicable in tissue banks
and as such, the results obtained can be expected to more
closely represent the actual chondrocyte viability achiev-
able in the clinical context. Worthwhile noticing is the fact
that human articular cartilage seems to be intrinsically
more difﬁcult to cryopreserve than cartilage from other spe-
cies,21 which is agreement with studies showing that the
structural features and organization of human articular car-
tilage differ considerably from those of other animal species
commonly used in orthopaedic research.22
Taken together, our results identify arbutin as a potential
new CPA for use with large human osteochondral allografts,
showing that it is more effective than DMSO or glycerol.
Nonetheless, improving other conditions, namely freezing
at a lower temperature, eventually by a step-cooling
method, and promoting a more complete diffusion of arbutin
through the cartilage, seems mandatory to signiﬁcantly in-
crease chondrocyte viability any further. One such possibil-
ity is the application of forces to the cartilage surface that
can drive the cryoprotective agent through it, as occurs
in vivo where joint motion drives the movement of nutrients
from the synovial ﬂuid into the articular cartilage.23 Develop-
ing mechanical devices that can apply the required forces
and combining them with highly effective CPAs, such as ar-
butin, may be the key to achieve a more complete protec-
tion of chondrocytes in the entire depth of the articular
cartilage and thus, to ensure the clinical success of cryopre-
served osteochondral allografts.
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